Cause and management of muscle wasting in chronic liver disease

Current Opinion in Gastroenterology

Volumn 32, Issue 3, 2016, Pages 159-165

  Dasarathy, Srinivasan ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hyperammonemia; Leucine supplementation; Mitochondrial function; Myostatin; Sarcopenia

Indexed keywords

2 OXOGLUTARIC ACID; ACETYL COENZYME A; AMINO ACID; FATTY ACID; MYOSTATIN; PYRUVIC ACID; TRICARBOXYLIC ACID;

AUTOPHAGY; CHRONIC LIVER DISEASE; CITRIC ACID CYCLE; DIET SUPPLEMENTATION; FATTY ACID OXIDATION; HUMAN; HYPERAMMONEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALNUTRITION; META ANALYSIS (TOPIC); MORTALITY; MUSCLE ATROPHY; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SARCOPENIA; SKELETAL MUSCLE; CHRONIC DISEASE; COMPLICATION; LIVER DISEASE; PATHOPHYSIOLOGY;

CHRONIC DISEASE; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; MALNUTRITION; SARCOPENIA;

EID: 84961231233     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000261     Document Type: Review

References (47)

1. Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis 2012; 16:95-131.
2. Maharshi S, Sharma BC, Srivastava S. Malnutrition in cirrhosis increases morbidity and mortality. J Gastroenterol Hepatol 2015; 30:1507-1513.
3. Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015; 31:193-199.
4. Merli M, Giusto M, Lucidi C, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis 2013; 28:281-284.
5. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology 1996; 23:1041-1046.
6. Merli M, Nicolini G, Angeloni S, Riggio O. Malnutrition is a risk factor in cirrhotic patients undergoing surgery. Nutrition 2002; 18:978-986.
7. Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for healthcareassociated bacterial infections. Clin Gastroenterol Hepatol 2010; 8:979-985.
8. Merli M, Giusto M, Gentili F, et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int 2010; 30:208-214.
9. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211:271-278.
10. Krell RW, Kaul DR, Martin AR, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013; 19:1396-1402.
11. Huisman EJ, Trip EJ, Siersema PD, et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol 2011; 23:982-989.
12. Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle 2012; 3:225-237.
13. McDaniel J, Davuluri G, Hill EA, et al. Hyperammonemia results in reduced muscle function independent of muscle mass. Am J Physiol Gastrointest Liver Physiol 2015; 310:G163-G170.
14. Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition 2005; 21:113-117.
15. Lai JC, Dodge JL, Sen S, et al. Functional decline in patients with cirrhosis awaiting liver transplantation: results from the Functional Assessment in Liver Transplantation (FrAILT) Study. Hepatology 2015; 63:574-580.
16. Dasarathy S. Treatment to improve nutrition and functional capacity evaluation in liver transplant candidates. Curr Treat Options Gastroenterol 2014; 12:242-255.
17. Dasarathy S, McCullough AJ, Muc S, et al. Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol 2011; 54:915-921.
18. Qiu J, Tsien C, Thapalaya S, et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab 2012; 303:E983-993.
19. Tsien C, Davuluri G, Singh D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology 2015; 61:2018-2029.
20. Jacobsen EB, Hamberg O, Quistorff B, Ott P. Reduced mitochondrial adenosine triphosphate synthesis in skeletal muscle in patients with Child-Pugh class B and C cirrhosis. Hepatology 2001; 34:7-12.
21. Gam CM, Nielsen HB, Secher NH, et al. In cirrhotic patients reduced muscle strength is unrelated to muscle capacity for ATP turnover suggesting a central limitation. Clin Physiol Funct Imaging 2011; 31:169-174.
22. Antar R, Wong P, Ghali P. A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol 2012; 26:463-467.
23. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev 2012; 5:CD008344.
24. Zenith L, Meena N, Ramadi A, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12:1920.e2-1926.e2.
25. Wu LJ, Wu MS, Lien GS, et al. Fatigue and physical activity levels in patients with liver cirrhosis. J Clin Nurs 2012; 21:129-138.
26. Jones JC, Coombes JS, Macdonald GA. Exercise capacity and muscle strength in patients with cirrhosis. Liver Transpl 2012; 18:146-151.
27. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10:166-173.
28. Glass C, Hipskind P, Tsien C, et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study. J Appl Physiol (1985) 2013; 114:559-565.
29. Merli M, Romiti A, Riggio O, Capocaccia L. Optimal nutritional indexes in chronic liver disease. JPEN J Parenter Enteral Nutr 1987; 11:130S-134S.
30. Dasarathy J, Alkhouri N, Dasarathy S. Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature. Liver Int 2011; 31:1250-1258.
31. Merli M. Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol 2015; 27:328-334.
32. Tsien C, Garber A, Narayanan A, et al. Postliver transplantation sarcopenia in cirrhosis: a prospective evaluation. J Gastroenterol Hepatol 2014; 29:1250-1257.
33. Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl 2012; 18:1209-1216.
34. Dasarathy S. Posttransplant sarcopenia: an underrecognized early consequence of liver transplantation. Dig Dis Sci 2013; 58:3103-3111.
35. Bergerson JT, Lee JG, Furlan A, et al. Liver transplantation arrests and reverses muscle wasting. Clin Transplant 2015; 29:216-221.
36. Underwood PW, Cron DC, Terjimanian MN, et al. Sarcopenia and failure to rescue following liver transplantation. Clin Transplant 2015; 29:1076-1080.
37. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol 2012; 27:430-441.
38. Qiu J, Thapaliya S, Runkana A, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. Proc Natl Acad Sci U S A 2013; 110:18162-18167.
39. Merli M, Giusto M, Molfino A, et al. MuRF-1 and p-GSK3beta expression in muscle atrophy of cirrhosis. Liver Int 2013; 33:714-721.
40. Thapaliya S, Runkana A, McMullen MR, et al. Alcohol-induced autophagy contributes to loss in skeletal muscle mass. Autophagy 2014; 10:677-690.
41. Holecek M, Kandar R, Sispera L, Kovarik M. Acute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentrations: different sensitivity of red and white muscle. Amino Acids 2011; 40:575-584.
42. Dam G, Ott P, Aagaard NK, Vilstrup H. Branched-chain amino acids and muscle ammonia detoxification in cirrhosis. Metab Brain Dis 2013; 28:217-220.
43. Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol 2013; 25:85-93.
44. Doi J, Shiraishi K, Haida M, Matsuzaki S. Abnormality of energy metabolism in the skeletal muscle of patients with liver cirrhosis and changes under administration of glucose and branched-chain amino acids. Tokai J Exp Clin Med 2004; 29:191-198.
45. Roman E, Torrades MT, Nadal MJ, et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. Dig Dis Sci 2014; 59:1966-1975.
46. You JS, Lincoln HC, Kim CR, et al. The role of diacylglycerol kinase zeta and phosphatidic acid in the mechanical activation of mammalian target of rapamycin (mTOR) signaling and skeletal muscle hypertrophy. J Biol Chem 2014; 289:1551-1563.
47. Lipton JO, Yuan ED, Boyle LM, et al. The circadian protein BMAL1 regulates translation in response to S6K1-mediated phosphorylation. Cell 2015; 161:1138-1151.